# A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors

> **NCT00923728** · NA · WITHDRAWN · sponsor: **Vertex Pharmaceuticals Incorporated**

## Conditions studied

- Refractory Solid Tumors

## Interventions

- **DRUG:** AVN944

## Key facts

- **NCT ID:** NCT00923728
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-04
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923728, "A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00923728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*